皮下与静脉CT-P13治疗类风湿关节炎的疗效、药代动力学和安全性:随机I/III期试验
这项在活动性RA且MTX应答不佳患者中开展的I/III期双盲研究显示,第22周时皮下CT-P13组DAS28-CRP下降2.21,静脉组下降1.94,差异0.27(95%CI 0.02, 0.52),达到非劣效界值-0.6,证实皮下非劣于静脉。第54周疗效相似,安全性相似,皮下给药便利。
要点
- 皮下CT-P13在活动性RA中第22周DAS28-CRP改善非劣于静脉制剂。
- 第54周两组疗效相似,安全性相似,无新安全信号。
- 皮下给药(预充式注射器或自动注射器)便利性相似。
核心结论
- 皮下CT-P13在活动性RA中疗效非劣于静脉CT-P13,皮下给药的便利性可能使患者获益。
研究设计与样本
- I/III期双盲研究,76个中心,活动性RA且MTX应答不佳患者先接受静脉CT-P13 3 mg/kg(第0和2周),第6周随机1:1至皮下CT-P13 120 mg每两周(至第28周)或静脉CT-P13 3 mg/kg每8周(至第22周)。
- 随机按国家、第2周血清CRP和第6周体重分层;第30周起所有患者接受皮下CT-P13;可用性子研究第46-54周使用自动注射器、第56-64周使用预充式注射器。
- 共入组357例,343例随机(皮下组167例,静脉组176例);主要终点为第22周DAS28-CRP较基线下降值,非劣效界值-0.6。
主要发现
- 第22周DAS28-CRP较基线最小二乘均值下降(标准误):皮下组2.21(0.22)(n=162),静脉组1.94(0.21)(n=168),差异0.27(95%CI 0.02, 0.52),确立非劣效性。
- 第54周两组疗效相似。
- 从第6周起治疗中出现不良事件:皮下组92例(54.8%),静脉组117例(66.9%);无治疗相关死亡或新安全发现。
- 皮下给药通过自动注射器或预充式注射器的可用性相似。
关键数值与推荐
- 主要终点非劣效界值:DAS28-CRP下降差异-0.6。
- 第22周DAS28-CRP下降差异0.27(95%CI 0.02, 0.52),满足非劣效。
临床怎么用
- 对于活动性RA且MTX应答不佳的患者,皮下CT-P13可作为静脉CT-P13的替代给药方式,便利性可能提高依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess non-inferiority of s.c. to i.v. CT-P13 in RA. METHODS: Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2] before randomization (1:1) at W6 to CT-P13 s.c. via pre-filled syringe (PFS) 120 mg biweekly until W28, or CT-P13 i.v. 3 mg/kg every 8 weeks until W22. Randomization was stratified by country, W2 serum CRP and W6 body weight. From W30, all patients received CT-P13 s.c. In a usability sub-study, patients received CT-P13 s.c. via auto-injector (W46-54) then PFS (W56-64). The primary endpoint was change (decrease) from baseline in disease activity score in 28 joints (DAS28)-CRP at W22 (non-inferiority margin: -0.6). RESULTS: Of 357 patients enrolled, 343 were randomized to CT-P13 s.c. (n = 167) or CT-P13 i.v. (n = 176) at W6. The least-squares mean change (decrease) from baseline (standard error) in DAS28-CRP at W22 was 2.21 (0.22) for CT-P13 s.c. (n = 162) and 1.94 (0.21) for CT-P13 i.v. [n = 168; difference 0.27 (95% CI: 0.02, 0.52)], establishing non-inferiority. Efficacy findings were similar between arms at W54. Safety was similar between arms throughout: 92 (54.8%; CT-P13 s.c.) and 117 (66.9%; CT-P13 i.v.) patients experienced treatment-emergent adverse events (from W6). There were no treatment-related deaths or new safety findings. Usability was similar for CT-P13 s.c. via auto-injector or PFS. CONCLUSION: CT-P13 s.c. was non-inferior to CT-P13 i.v. in active RA. The convenience of s.c. administration could benefit patients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03147248.
引用
- Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2021. PMID: 33230526. doi:10.1093/rheumatology/keaa580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。